Boston Scientific (NYSE:BSX) shares have seen a significant bump today after the company released preliminary fourth quarter and fiscal year 2017 earnings that topped The Street and showed growth of approximately 9.9% and 7.9%, respectively.
For the fourth quarter, the Marlborough, Mass.-based company said it expects to report sales of $2.4 billion, just in line with the approximate $2.4 billion consensus on Wall Street.
The quarterly results represent 9.9% growth on a reported basis, 8.1% on an operational basis and approximately 6.8% on an organic basis, the company said in a press release.
For the full year, Boston Scientific said it expects to report sales of $9.1 billion, which is just ahead of the $9 billion consensus on The Street and representing growth of 7.9% on a reported basis. 7.8% on an operational basis and 6.6% on an organic basis.
Shares in Boston Scientific have risen 8.2% so far today, at $27.92 as of 3:16 p.m. EST.
Last month, Boston Scientific said it won FDA approval for its Vercise deep brain stimulation system designed to treat symptoms of Parkinson’s disease.
Early rates for DeviceTalks Boston end August 15th.
Don't miss the chance to save $100 and join top medtech innovators including leaders from Hologic, Google, Gray Matter, TransEnterix, NxStage Medical, Smith & Nephew, HeartFlow, Dynatronics, Johnson & Johnson, Allied Minds, and many more.
View Full Agenda
Register today to save. Use code LASTCALL to save an additional 10%.